DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
COR logo

Cencora, Inc. Stock Price

NYSE:COR Community·US$61.2b Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 56 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

COR Share Price Performance

US$321.57
19.05 (6.30%)
​
US$372.58
Fair Value
US$321.57
19.05 (6.30%)
13.7% undervalued intrinsic discount
US$372.58
Fair Value
Price US$321.57
AnalystConsensusTarget US$372.58
AnalystLowTarget US$330.00
Wed, 19 Aug 26
Fair ValueUS$372.58
Share Pricen/a

COR Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$372.58 13.7% undervalued intrinsic discount

COR: Ongoing Litigation Settlement And Buybacks Will Shape Healthcare Delivery Evolution

0users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$330 2.6% undervalued intrinsic discount

Specialty And AI Investments Will Shape A Stable Yet Constrained Future Trajectory

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
COR logo
Cencora
13.7% undervalued intrinsic discount

COR: Ongoing Litigation Settlement And Buybacks Will Shape Healthcare Delivery Evolution

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 19 Aug
Read Narrative
COR logo
Cencora
2.6% undervalued intrinsic discount

Specialty And AI Investments Will Shape A Stable Yet Constrained Future Trajectory

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 3 Sep
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
COR logo

COR: Fair View Will Weigh Therapy Enablement Push And Nucleus Pilot Outcomes

Fair Value: US$330 2.6% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
COR logo

COR: Expanded Buybacks And Higher 2026 EPS Guidance Will Support Long-Term Upside

Fair Value: US$372.58 13.7% undervalued intrinsic discount
25 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Solid track record, good value and pays a dividend.

2 Risks
3 Rewards
View Full Analysis

Cencora, Inc. Key Details

US$332.8b

Revenue

US$319.6b

Cost of Revenue

US$13.2b

Gross Profit

US$10.6b

Other Expenses

US$2.6b

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
13.75
3.96%
0.79%
361.9%
View Full Analysis

About COR

Founded
1871
Employees
49000
CEO
Robert Mauch
WebsiteView website
www.cencora.com

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Recent COR News & Updates

User avatar
Narrative Update • Sep 03

COR: Fair View Will Weigh Therapy Enablement Push And Nucleus Pilot Outcomes

Analysts now cite a $10 rise in their Cencora price target to $330, reflecting updated views on fair value, discount rate, revenue growth assumptions and profit margin outlooks, while still applying a similar future P/E framework. What’s in the News for Cencora Cencora’s Accelerate Pharmacy Solutions unit launched a Cell and Gene Therapy Enablement service that is designed to help health systems build and scale cell and gene therapy programs, with tailored support around financial confidence, operational readiness and scalable growth.

Recent updates

No updates

Cencora, Inc. Competitors

UNH logo

UnitedHealth Group

Symbol: NYSE:UNH
Market cap: US$348.5b
ABT logo

Abbott Laboratories

Symbol: NYSE:ABT
Market cap: US$178.9b
ISRG logo

Intuitive Surgical

Symbol: NasdaqGS:ISRG
Market cap: US$127.3b
CVS logo

CVS Health

Symbol: NYSE:CVS
Market cap: US$121.9b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide